Table 4. First-administrated and actual drug regimens while failing treatment.
| Drug | First cART regimens (n = 165)a | Actual regimens when genotyped (n = 78)b | |||
| Number | Percent | Number | Percent | ||
| PI | LPV/r | 53 | 32.1% | 24 | 30.8% |
| Other Boosted PI | 14 | 8.5% | 2 | 2.6% | |
| Non boosted PI | 21 | 12.7% | 8 | 10.3% | |
| 18.5±2.5 | Total | 88 | 53.3% | 34 | 43.6% |
| NRTI | TDF+FTC | 84 | 50.9% | 34 | 43.6% |
| ZDV+3TC | 51 | 30.9% | 18 | 23.1% | |
| Others | 30 | 18.2% | 26 | 33.3% | |
| 20.5±2.3 | Total | 165 | 100.0% | 78 | 100.0% |
| NNRTI | EFV | 71 | 43.0% | 33 | 42.3% |
| NVP | 6 | 3.6% | 6 | 7.7% | |
| 24±3.3 | Total | 77 | 46.7% | 39 | 50.0% |
a
All except 5 received NRTIs as part of the first regimen. A few received mono- or duo-therapy or combinations of PIs and NNRTIs.
b
All 78 treatment-failing patients received NRTI backbone. Thirty-four received also PI and 39 NNRTI as additional drug.
3TC – lamivudine; EFV – efavirenz; FTC – emtricitabine; LPV/r – lopinavir/r; NNRTI – Non-Nucleoside Reverse Trancriptase Inhibitor; NRTI – Nucleoside Reverse Trancriptase Inhibitor; NVP – nevirapine; PI – Protease inhibitor; r – ritonavir; TDF – tenofovir; ZDV – zidovudine.